

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine

SWIFT

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine

SWIFT: Study Design

Study Design: SWIFT


- **Background:** Prospective, randomized, open-label study to evaluate the efficacy and safety of a switch from ABC-3TC to TDF-FTC in virologically suppressed patients taking a RTV-boosted PI
- **Inclusion Criteria:**
 - Adults with HIV infection
 - Men and nonpregnant women
 - Receiving ABC-3TC + RTV-boosted PI (and no additional ARV agents)
 - No resistance to any study drug
 - HIV RNA <200 copies/mL ≥ 3 months
 - eGFR ≥ 50 mL/min
 - AST/ALT ≤ 5 x upper limit of normal,
 - If on a lipid-lowering agent then stable dose x ≥ 3 months

Switch to TDF-FTC + PI/r
(n = 155)

Continue ABC-3TC + PI/r
(n = 156)

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine SWIFT: Results


Week 48 Virologic Response (by TLOVR, Intention-to-Treat Analysis)



Source: Campo R, et al. Clin Infect Dis. 2013;56:1637-45.

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine SWIFT: Results

Week 48 Virologic Failure (Intention-to-Treat Analysis)




All 3 subjects with virologic failure in the TDF-FTC arm had low-level viremia (209-452 copies/mL)
No genotypic resistance was observed with virologic failure in either arm

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine

SWIFT: Results

Week 48: Change in Plasma Lipids from Baseline



Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine

SWIFT: Results

SWIFT Trial Results: Adverse Events (AE's)		
	TDF-FTC + RTV + PI (n = 155)	ABC-3TC + RTV + PI (n = 156)
Any AE	112 (72.3%)	120 (76.9%)
Grade 3 or 4 AE	13 (8.4%)	16 (10.3%)
AE related to study drug	16 (10.3%)	6 (3.8%)
Grade 3-4 AE related to study drug	1 (0.6%)	0 (0%)
AE leading to study drug discontinuation	7 (4.5%)	3 (1.9%)
Renal AE	7 (4.5%)	8 (5.1%)
Change in eGFR (baseline to 48 weeks, Cockcroft-Gault)	-8.3 mL/min	-4.5 mL/min

Switch from Abacavir-Lamivudine to Tenofovir DF-Emtricitabine SWIFT: Results

Conclusion: “Switching to FTC/TDF from 3TC/ABC maintained virologic suppression, had fewer VFs, improved lipid parameters and Framingham scores but decreased eGFR.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

